Genmab A/S Sponsored ADR (GMAB)
Market Closed
16 Oct, 08:00 PM
$
37. 00
-0.82
-2.1682%
$
23.26B Market Cap
30.3 P/E Ratio
- Div Yield
2.68M Volume
11.27 Eps
$ 37.82
Previous Close 
Want to track GMAB and more in your Portfolio? 🎯
Sign up for Marketlog, a portfolio tracker that will exceed your expectations!
Down -14.68% in 4 Weeks, Here's Why Genmab (GMAB) Looks Ripe for a Turnaround
Genmab (GMAB) has become technically an oversold stock now, which implies exhaustion of the heavy selling pressure on it. This, combined with strong agreement among Wall Street analysts in revising earnings estimates higher, indicates a potential trend reversal for the stock in the near term.
Zacks | 2 years ago
Buy 2 Biotech Bigwigs Set to Gain on Possible Earnings Beat
Two biotech bigwigs set to beat on earnings next week are: ILMN, GMAB.
Zacks | 2 years ago
2026 © Marketlog. All Rights Reserved.
